Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vemurafenib + cobimetinib with PET response monitoring in BRAF V600-mutant advanced melanoma
2014-002480-15Phase 2Active
- Sponsor
- WIN-O
- Start
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of vemurafenib and cobimetinib in melanoma, sponsored by WIN-O. Primary endpoint: Progression-free survival. Started Oct 2014; status: active.
02
Drugs
vemurafenibcobimetinib
03
Conditions
melanoma
Beyond the preview
Go deeper on 2014-002480-15.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002480-15.